Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Treatment of Non-small Cell Lung Cancer With CIK Cells Blocked by PD-1 Antibody

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03282435

Enrollment

Registered

2017-09-14

Start date

2018-01-31

Completion date

2023-01-31

Last updated

2017-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Brief summary

to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy

Interventions

BIOLOGICALCIK cells with PD-1 blocking

CIK cellular therapy with PD-1 blocking

OTHERstandard lung cancer treament

standard non-small cell lung cancer treatment: surgery, chemotherapy

BIOLOGICALCIK cells without PD-1 blocking

CIK cellular therapy without PD-1 blocking

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

* non-small cell lung cancer; * more than 50% tumor tissues positive with PD-L1; * EGFR and ALK wild type * no other tumors

Exclusion criteria

* with systematic diseases shortening survival

Design outcomes

Primary

Measure	Time frame
progression-free survival	5 years
metastasis-free survival	5 years

Contacts

Primary Contacthaoren wang

haoren_wang@yahoo.com86-041162893507

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026